Perforations and Fistulas and Hemorrhage
- Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of cabozantinib s-malate treated patients . Discontinue cabozantinib s-malate for perforation or for fistula formation (See Warnigns and Precaution).
- Hemorrhage: Severe, sometims fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of cabozantinib s-malate-treated patients. Monitor patients for signs and symptoms of bleeding. Do not administer cabozantinib s-malate in patients with severe hemorrhage.
Patient Counseling Information
Updated January 2018